WASHINGTON - President Donald Trump said on Friday he intends to nominate Stephen Hahn, the chief medical officer of MD Anderson Cancer Center in Houston, as the next commissioner of the Food and Drug Administration, a step that resulted in musical chairs involving some of the government’s highest-ranking health jobs.
In a surprise move, acting FDA commissioner Norman “Ned” Sharpless, will immediately return to his previous position as the director of the National Cancer Institute. Brett Giroir, assistant secretary for health at the Department of Health and Human Services, will oversee the FDA until Dr. Hahn is confirmed, according to HHS Secretary Alex Azar.
It had been assumed that Dr. Sharpless would run the FDA until Dr. Hahn was confirmed. However, his term as acting agency head expired Friday. It couldn’t be extended because the White House has not yet officially nominated Dr. Hahn, who is still undergoing a background check, officials said. When Dr. Sharpless returns to the NCI, Doug Lowy, acting director of the cancer institute, will resume his work as principal deputy there.
The movement on Dr. Hahn’s nomination is occurring at a critical time for the agency, which is at the center of a debate about banning almost all flavors in e-cigarettes - an action intended to stem sharp increases in youth vaping. Mr. Trump announced plans for a broad ban in September, but the agency has not yet issued its final policy. Recently, two people familiar with the discussions said the White House is considering excluding menthol and possibly mint from the ban because of concerns about political backlash from vaping supporters.
Dr. Hahn, a radiation and medical oncologist, oversees clinical care at MD Anderson, one of the nation’s top cancer centers. Previously, he served as chief operating officer of the hospital during a period of big losses and staff cuts, and has been praised for helping engineer the cancer center’s financial turnaround.
Sen. Lamar Alexander, R.-Tenn., chairman of the Health, Education, Labor and Pensions Committee, said he looked forward to meeting Dr. Hahn. He plans to move “as expeditiously as possible” to confirm Dr. Hahn and bring “certainty” to the agency, a committee spokesman said.
Sen. Patty Murray, D-Wash., the ranking member of the committee, said she planned to vet Dr. Hahn thoroughly to determine if he is qualified to be FDA commissioner and will press him to quickly impose a comprehensive ban on flavored e-cigarettes.
She added she was “alarmed” by the appointment of Dr. Giroir as interim FDA chief, saying that he has a “track record of letting ideology drive decisions at the expense of women and families.” An aide said the senator was referring to Dr. Giroir’s involvement in policy changes that reduce women’s access to health care, in particular reproductive rights.
When asked for a response to Ms. Murray’s comment about Dr. Giroir, a spokeswoman for HHS pointed to Mr. Azar’s statement, which called him “an indispensable leader” for HHS on several public health priorities.
One of the most high-profile issues Dr. Giroir has been involved in is federal funding for fetal tissue research. Last December, Dr. Giroir said at a private meeting of scientists that the government would continue to fund research by nongovernment scientists. Last summer, however, Mr. Trump decided to end federal funding of the research for government researchers and strictly limit funding for academic researchers. Mr. Azar and his aides pushed for a less restrictive position, The Washington Post reported at the time.
A medical and radiation oncologist, Dr. Hahn is described by friends and colleagues as an energetic consensus-builder with a disarming, folksy manner. After a stint at NCI, he joined the University of Pennsylvania in 1996, serving as chair of radiation oncology from 2005 to 2014. He then moved to MD Anderson to become division head of radiation oncology. He has conducted an array of clinical trials, including trials of treating prostate cancer with proton therapy and new ways to combine immunotherapy and radiation.
If confirmed, Dr. Hahn would head an agency that regulates a broad swath of the U.S. economy, including brand-name and generic drugs, medical devices, much of the nation’s food supply and tobacco products.
Dr. Hahn, who is married and has four adult children, is an exercise enthusiast and avid football fan. He and his wife, friends say, travel frequently to Italy.
Dr. Sharpless, an oncologist who also was a contender for the FDA job on a permanent basis, had been acting FDA commissioner since April, when the previous agency head, Scott Gottlieb, stepped down. He had strong support from medical and other groups. On Friday, Mr. Azar praised Dr. Sharpless for making progress on key issues such as youth use of tobacco and prescription drug costs.





Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.